Enliven Therapeutics, Inc. (ELVN) Insider Trading -- Recent Executive & Director Transactions

11 insiders reported 178 Form 4 transactions for Enliven Therapeutics, Inc. (ELVN) over the past 18 months (most recent 2026-08-19). Recent activity: Hohl Benjamin (CHIEF FINANCIAL OFFICER) Sell 4,630 shares, Collins Helen Louise (CHIEF MEDICAL OFFICER) Buy 5,000 shares, Collins Helen Louise (CHIEF MEDICAL OFFICER) Sell 3,900 shares, Hohl Benjamin (CHIEF FINANCIAL OFFICER) Sell 1,388 shares, Collins Helen Louise (CHIEF MEDICAL OFFICER) Sell 1,100 shares. Source: SEC Form 4.

DateInsiderTitleTypeSharesValue
2026-08-19Hohl BenjaminCHIEF FINANCIAL OFFICERSell4,630$270,168
2026-08-19Collins Helen LouiseCHIEF MEDICAL OFFICERBuy5,000$12,400
2026-08-19Collins Helen LouiseCHIEF MEDICAL OFFICERSell3,900$227,650
2026-08-19Hohl BenjaminCHIEF FINANCIAL OFFICERSell1,388$82,383
2026-08-19Collins Helen LouiseCHIEF MEDICAL OFFICERSell1,100$65,281
2026-08-06Derynck Mika KDirectorBuy87,373$216,685
2026-08-06Derynck Mika KDirectorBuy27,567$696,894
2026-08-06Derynck Mika KDirectorBuy23,364$346,955
2026-08-06Derynck Mika KDirectorBuy20,491$460,433
2026-08-06Derynck Mika KDirectorSell158,795$9.6M
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERSell231$11,563
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERBuy1,072$2,659
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERBuy5,000$12,400
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERSell324$16,191
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERSell459$23,660
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERSell369$18,997
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERSell2,063$108,085
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERSell2,564$134,143
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERSell2,184$116,669
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERSell2,638$140,823
2026-07-21Collins Helen LouiseCHIEF MEDICAL OFFICERSell63$3,397
2026-07-21Hohl BenjaminCHIEF FINANCIAL OFFICERSell123$6,626
2026-07-08Kunkel Lori AnneDirectorSell4,111$205,482
2026-07-08Kunkel Lori AnneDirectorSell5,889$299,421
2026-06-24ORBIMED ADVISORS LLC10% OwnerSell24,846$1.1M

Source: SEC Form 4 filings · as of 2026-08-19